4.3 Editorial Material

Chronic Diseases: The Emerging Pandemic

期刊

CTS-CLINICAL AND TRANSLATIONAL SCIENCE
卷 4, 期 3, 页码 225-226

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1752-8062.2011.00295.x

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Pharmacology & Pharmacy

Managing Innovation to Maximize Value Along the Discovery-Translation-Application Continuum

S. A. Waldman, A. Terzic

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

Article Cardiac & Cardiovascular Systems

Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Jozef Bartunek, Andre Terzic, Beth A. Davison, Gerasimos S. Filippatos, Slavica Radovanovic, Branko Beleslin, Bela Merkely, Piotr Musialek, Wojciech Wojakowski, Peter Andreka, Ivan G. Horvath, Amos Katz, Dariouch Dolatabadi, Badih El Nakadi, Aleksandra Arandjelovic, Istvan Edes, Petar M. Seferovic, Slobodan Obradovic, Marc Vanderheyden, Nikola Jagic, Ivo Petrov, Shaul Atar, Majdi Halabi, Valeri L. Gelev, Michael K. Shochat, Jaroslaw D. Kasprzak, Ricardo Sanz-Ruiz, Guy R. Heyndrickx, Noemi Nyolczas, Victor Legrand, Antoine Guedes, Alex Heyse, Tiziano Moccetti, Francisco Fernandez-Aviles, Pilar Jimenez-Quevedo, Antoni Bayes-Genis, Jose Maria Hernandez-Garcia, Flavio Ribichini, Marcin Gruchala, Scott A. Waldman, John R. Teerlink, Bernard J. Gersh, Thomas J. Povsic, Timothy D. Henry, Marco Metra, Roger J. Hajjar, Michal Tendera, Atta Behfar, Bertrand Alexandre, Aymeric Seron, Wendy Gattis Stough, Warren Sherman, Gad Cotter, William Wijns

EUROPEAN HEART JOURNAL (2017)

Article Food Science & Technology

ST-Producing E-coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice

Peng Li, Jieru E. Lin, Adam E. Snook, Scott A. Waldman

TOXINS (2017)

Review Pharmacology & Pharmacy

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer

Allison A. Aka, Jeff A. Rappaport, Amanda M. Pattison, Takami Sato, Adam E. Snook, Scott A. Waldman

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)

Article Gastroenterology & Hepatology

Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders

Scott A. Waldman, Michael Camilleri

Review Medicine, Research & Experimental

Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies

John C. Flickinger, Jeffrey A. Rappaport, Joshua R. Barton, Trevor R. Baybutt, Amanda M. Pattison, Adam E. Snook, Scott A. Waldman

Summary: GUCY2C has emerged as a promising target for gastrointestinal cancers, with current focus on colorectal cancer, the most prevalent gastrointestinal malignancy. Targeted therapies aimed at GUCY2C show potential for prevention, detection, and treatment of these tumors.

BIOMARKERS IN MEDICINE (2021)

Review Pharmacology & Pharmacy

Stem cells as therapeutic targets in colorectal cancer

Alicja Zalewski, Adam E. Snook, Scott A. Waldman

Summary: Colorectal cancer is the second leading cause of cancer mortality in the US, with 50% of patients presenting with late-stage metastatic disease or experiencing metastatic recurrences, ultimately succumbing to cancer stem cells. Targeting colorectal cancer stem cells is a crucial therapeutic approach for eradicating the disease.

PERSONALIZED MEDICINE (2021)

Review Medicine, Research & Experimental

Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers

Lara Cheslow, Adam E. Snook, Scott A. Waldman

Summary: Parkinson's disease is a highly prevalent and irreversible neurodegenerative disorder with no approved biomarkers to reliably identify patients before extensive neuronal damage. Recent research exploring mechanisms underlying PD progression challenges the classic view of PD as a brain-isolated disease, leading to potential new biomarker candidates from multiple sites in the body.

BIOMARKERS IN MEDICINE (2021)

Review Pharmacology & Pharmacy

Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer

Adi Caspi, Ariana A. Entezari, Madison Crutcher, Adam E. Snook, Scott A. Waldman

Summary: Colorectal cancer is a major cause of mortality in the USA, and while current therapies focus on generic treatment, there is a growing need for effective targets and biomarkers. Guanylyl cyclase C, which regulates intestinal homeostasis and is universally expressed in advanced metastatic colorectal tumors, has emerged as a promising target and biomarker for gastrointestinal malignancies.

PERSONALIZED MEDICINE (2022)

Article Immunology

Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy

John C. Flickinger, Ross E. Staudt, Jagmohan Singh, Robert D. Carlson, Joshua R. Barton, Trevor R. Baybutt, Jeffrey A. Rappaport, Alicja Zalewski, Amanda Pattison, Scott A. Waldman, Adam E. Snook

Summary: Strategies to enhance immunity to self/neoantigens expressed by cancers are urgently needed. This study explored a prime-boost strategy combining a chimeric adenoviral vector and recombinant Listeria monocytogenes to amplify GI cancer antigen GUCY2C-specific immunity. The combination enhanced the efficacy of effector CD8(+) T cells without toxicity and resistance to pre-existing immunity.

NPJ VACCINES (2022)

Article Medicine, Research & Experimental

Intestinal neuropod cell GUCY2C regulates visceral pain

Joshua R. Barton, Annie K. Londregran, Tyler D. Alexander, Ariana A. Entezari, Shely Bar-Ad, Lan Cheng, Angelo C. Lepore, Adam E. Snook, Manuel Covarrubias, Scott A. Waldman

Summary: GUCY2C signaling in neuropod cells plays a crucial role in visceral pain, and FDA-approved GUCY2C agonists can alleviate visceral pain in patients with chronic constipation syndromes. Studies on neural currents and action potentials indicate that neuropod cells, enriched with GUCY2C receptors, have significant regulatory effects.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Review Pharmacology & Pharmacy

Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential

Ariana A. Entezari, Adam E. Snook, Scott A. Waldman

Summary: GUCY2C has emerged as a promising target for chemoprevention and therapy for GI malignancies, with potential roles in immunotherapy and diagnostic management as well. Clinical trials are underway to explore its use as an immunotherapeutic target for preventing metastatic disease. GUCY2C is an emerging target across the disease continuum, from chemoprevention to the prevention of metastatic diseases.

EXPERT OPINION ON THERAPEUTIC TARGETS (2021)

Article Oncology

GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome

Peng Li, Evan Wuthrick, Jeff A. Rappaport, Crystal Kraft, Jieru E. Lin, Glen Marszalowicz, Adam E. Snook, Tingting Zhan, Terry M. Hyslop, Scott A. Waldman

CANCER RESEARCH (2017)

Article Oncology

Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis

Q. Wei, Z. Ye, X. Zhong, L. Li, C. Wang, R. E. Myers, J. P. Palazzo, D. Fortuna, A. Yan, S. A. Waldman, X. Chen, J. A. Posey, A. Basu-Mallick, B. H. Jiang, L. Hou, J. Shu, Y. Sun, J. Xing, B. Li, H. Yang

ANNALS OF ONCOLOGY (2017)

Article Oncology

Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention

David S. Weinberg, Jieru E. Lin, Nathan R. Foster, Gary Della'Zanna, Asad Umar, Drew Seisler, Walter K. Kraft, David M. Kastenberg, Leo C. Katz, Paul J. Limburg, Scott A. Waldman

CANCER PREVENTION RESEARCH (2017)

暂无数据